Changing biodelivery

enabling oral peptide delivery enabling nasal protein delivery

CYPRUMED GmbH, established in 2015, is an Austrian drug delivery company developing enabling technologies for the non-invasive delivery of biologics, with a focus on oral peptide delivery. Key activities include formulation research, IP protection and technology out-licensing.
Technology
About
Collaborate
Projects
News

Our IP protected technology offers several advantages…

Our IP protected technology

offers several advantages…

Increasing bioavailability without drug alteration IP protected platform technology Safe, cost effective & simple to scale up

Efficacy

Proof of concept with various peptides, proteins & antibodies

IPR

Several patents filed, first European and US patents granted

Regulatory

Key excipients: FDA inactive ingredient list, GRAS status, USP/EP monographs

FMC

Low cost excipients, multiple suppliers, easy to scale up and produce under GMP

Shelf life

Storage stability at room temperature confirmed

Mechanism

Bioavailability increase via unaltered drug protection & improved drug transport

Efficacy

Proof of concept with various peptides, proteins & antibodies

IPR

Several patents filed, first patents granted

Regulatory

Key excipients: FDA inactive ingredient list, GRAS status, USP/EP monographs

FMC

Low cost excipients, multiple suppliers, easy to scale up and produce under GMP

Shelf life

Storage stability at room temperature confirmed

Mechanism

Bioavailability increase via unaltered drug protection & improved drug transport

Our Team

Management Team

Advisory Board

Dr. Florian Föger
Dr. Martin Werle
Dr. Jürg Meier
Dr. Uwe Jacob
Dr. Ruedi Wäger

CYPRUMED R&D Center: Eduard Bodem Gasse 8, 6020 Innsbruck, AUSTRIA

Collaborate with us!

You can leverage our expertise and network in the fields of
  • oral formulation development (tablets, capsules, intestinal targeting)
  • nasal formulation development
  • formulation prototype production for non-clinical studies
  • in vitro protease stability assessment
  • in vitro permeation studies
  • in vivo pharmacokinetic studies in rats, pigs, dogs and non-human primates via our CRO network

You can leverage our expertise and network in the fields of

  • oral formulation development (tablets, capsules, intestinal targeting)
  • nasal formulation development
  • formulation prototype production for non-clinical studies
  • in vitro protease stability assessment
  • in vitro permeation studies
  • in vivo pharmacokinetic studies in rats, pigs, dogs and non-human primates via our CRO network

Collaboration contact

info@cyprumed.net

 

We are currently engaged

in various pre-clinical

projects…

News

dummy

October

US Patent granted

September

ORF (Austrian Broadcasting Corporation) features an article on Cyprumed research activities

Grant of FFG Funding (Österreichische Forschungsförderung)

April

Grant of FFG Funding (Österreichische Forschungsförderung)

July

Cyprumed establishes new R&D Center in Innsbruck

December

European Patent granted

June

Grant of FFG Funding (Österreichische Forschungsförderung)

April

European Patent granted

July

Cyprumed awarded at the Science4Life Venture Cup

from left: Dr. Martin Werle (COO Cyprumed), Minister for Economic Affairs (Hessen, Germany) Tarek Al-Wazir,
Dr. Florian Föger (CEO Cyprumed), Prof. Dr. Jochen Maas (Head of R&D Sanofi-Aventis Germany)
March

Cyprumed wins concept phase at the Science4Life Venture Cup 2016

from left: Secretary of state (Hessen, Germany) Mathias Samson, Dr. Florian Föger (CEO Cyprumed), Dr. Martin Werle (COO Cyprumed),
Dr. Karl-Heinz Baringhaus, Head of R&D Sanofi-Aventis Deutschland GmbH
February

Cyprumed announces the appointment of Dr. Martin Werle, MBA as Chief Operating Officer

from left: Dr. Martin Werle, Dr. Florian Föger
November

Cyprumed receives AWS Seedfinancing

May

Cyprumed wins first prize of Best of Biotech competition (Phase 2)

from left: Daniel Föger & Florian Föger (Cyprumed), Wolfram Schmidt (Roche Austria), Eva Prieschl-Grassauer (Marinomed), Ulrike Unterer (BMWFW)
April

AWS funded Cyprumed receives Start-up award from Secretary of State Harald Mahrer

from left: Florian Föger (Cyprumed) and Harald Mahrer (BMWFW)
December

Cyprumed receives preseed grant from AWS

November

Cyprumed wins first prize of Best of Biotech competition (Phase 1)

July

Dr. Florian Föger wins first prize of AdventureX business competition

from left: Florian Föger (Cyprumed) and Patrizia Zoller-Frischauf (Member of the Tyrolean Government)
© 2021 - CYPRUMED® All Rights Reserved
Imprint/Data Protection

Dr. Florian Föger

Chief Executive Officer

Florian Föger is the founder of Cyprumed GmbH and the inventor of its next generation drug delivery technology. Previously, Florian Föger was Director of Oral Formulation Research at Novo Nordisk A/S in Denmark. He is the inventor of more than 10 patent applications in the field of oral peptide delivery and author of 17 peer reviewed research articles in the oral delivery field. Florian Föger received a PhD in Pharmaceutical Sciences from the University of Innsbruck, Austria.

Dr. Martin Werle, MBA

Chief Operating Officer

Martin Werle held various leadership and management positions in formulation development, corporate strategy and global R&D project management at Syngenta AG, Basel, Switzerland. In addition, he has many years of international experience as scientist and project leader in the area of oral peptide delivery, in both, academia and start-ups. Martin Werle has published more than 30 peer reviewed research articles and book contributions in the field of drug delivery. He received an MBA from SMC University, Switzerland and a PhD in Pharmaceutical Technology from the University of Innsbruck, Austria.

Dr. Jürg Meier

Chairman of Advisory Board

Jürg Meier was the Executive Director of the Novartis Venture Fund for eight years. Previously, he was working over 25 years in various international management functions of the former company Sandoz Pharma Ltd., holding positions such as Head of R&D Biochemie GmbH Austria, Head of R&D Sandoz USA and worldwide and President of Sandoz Pharma Japan. During eight years he was a member of the Swiss National Science Foundation and supervised three NCCR programs (National Centers of Competence in Research). Jürg Meier was Chairman of Polyphor AG and of Cardiolynx AG and a Board Member of Tecan AG, BioMed Invest AG and Solvias AG. Today Jürg Meier consults entrepreneurs and start-up companies.

Prof. Dr. Uwe Jacob

Member of Advisory Board

Uwe Jacob was the main founder and first CEO of SuppreMol GmbH. Later he was holding the position of the Chief Scientific Officer and the Chief Development Officer. In parallel Uwe Jacob is teaching biochemistry at the Gene Center, Munich. Before working with SuppreMol he was assistant Professor at the Ludwig Maximilians University of Munich and a group leader at the Max Planck Institute of Biochemistry. Uwe Jacob studied biochemistry at the Medizinische Hochschule Hannover and the University of Southern California. He finalized his PhD thesis in X-ray crystallography in the department of Prof. Huber at the Max Planck Institute of Biochemistry. Afterwards Uwe Jacob continued his career as a post doctoral scientist at Roche Pharmaceuticals where he also finished his habilitation program.

Dr. Ruedi Wäger

Member of Advisory Board

Ruedi Wäger was the President and Chief Executive Officer of Aventis Behring L.L.C.. Previously, he was President and Chief Executive Officer of ZLB Central Laboratories, Blood Transfusion Service of Swiss Red Cross, and spent more than 20 years at Sandoz Ltd., where he had consecutive worldwide responsibilities for Strategic Research and Development Planning, Human Resource Management, and Marketing. Ruedi Wäger currently sits on the board of various biopharmaceutical companies. He earned a Ph.D. in Biochemistry from the Swiss Federal Institute of Technology.